Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rameen Beroukhim, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Rameen Beroukhim and Andrew Cherniack.
Connection Strength

2.070
  1. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 08 25; 37(16):2461-2463.
    View in: PubMed
    Score: 0.248
  2. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun. 2020 05 20; 11(1):2517.
    View in: PubMed
    Score: 0.227
  3. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 2020 05 11; 37(5):639-654.e6.
    View in: PubMed
    Score: 0.227
  4. Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2017 06 30; 7:46873.
    View in: PubMed
    Score: 0.186
  5. Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 06 24; 6:27960.
    View in: PubMed
    Score: 0.173
  6. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 05 10; 6:25521.
    View in: PubMed
    Score: 0.172
  7. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
    View in: PubMed
    Score: 0.143
  8. Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
    View in: PubMed
    Score: 0.061
  9. Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. STAR Protoc. 2021 Jun 18; 2(2):100483.
    View in: PubMed
    Score: 0.060
  10. Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 23; 34(8):108784.
    View in: PubMed
    Score: 0.060
  11. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 02 02; 34(5):108707.
    View in: PubMed
    Score: 0.060
  12. Ancestry-specific predisposing germline variants in cancer. Genome Med. 2020 05 29; 12(1):51.
    View in: PubMed
    Score: 0.057
  13. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
    View in: PubMed
    Score: 0.056
  14. PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):334-345.
    View in: PubMed
    Score: 0.051
  15. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018 04 09; 33(4):676-689.e3.
    View in: PubMed
    Score: 0.049
  16. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016 08; 48(8):848-55.
    View in: PubMed
    Score: 0.043
  17. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28; 164(3):550-63.
    View in: PubMed
    Score: 0.042
  18. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
    View in: PubMed
    Score: 0.041
  19. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View in: PubMed
    Score: 0.040
  20. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget. 2015 Jan 20; 6(2):1327-39.
    View in: PubMed
    Score: 0.039
  21. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.